NasVax develops improved vaccines and immunotherapeutic products. The company has four distinct product areas: i. oral anti-CD3 monoclonal antibody immunotherapeutic; ii. VaxiSome® technology, which is an adjuvant-delivery system for enhancing the immunogenicity of vaccines and immunotherapeutics; iii. group-common pneumococcal vaccine, which is a protein-based vaccine that could become the field’s third-generation product; and iv. BBS1-based immunotherapeutics for Alzheimer’s disease.